Page last updated: 2024-11-02

pioglitazone and Diabetic Angiopathies

pioglitazone has been researched along with Diabetic Angiopathies in 80 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging."9.15Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011)
" This study aims to assess the effect of pioglitazone on the vasculature of patients with impaired glucose tolerance (IGT)."9.14Effect of pioglitazone on endothelial function in impaired glucose tolerance. ( Hamilton, PK; Lockhart, CJ; Loughrey, CM; McVeigh, GE; Quinn, CE, 2010)
"Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure."9.12Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). ( Charbonnel, B; Dormandy, JA; Erdmann, E; Massi-Benedetti, M; Skene, AM; Spanheimer, R; Standl, E; Tan, M; Wilcox, RG; Yates, J, 2007)
" This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model."7.85Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017)
"This study of patients with Type 2 diabetes failed to find evidence that short-term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first-line diabetes therapy."5.33Pioglitazone initiation and subsequent hospitalization for congestive heart failure. ( Ahmed, AT; Karter, AJ; Liu, J; Moffet, HH; Parker, MM, 2005)
"The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging."5.15Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011)
" This study aims to assess the effect of pioglitazone on the vasculature of patients with impaired glucose tolerance (IGT)."5.14Effect of pioglitazone on endothelial function in impaired glucose tolerance. ( Hamilton, PK; Lockhart, CJ; Loughrey, CM; McVeigh, GE; Quinn, CE, 2010)
" The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline."5.14Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). ( Charbonnel, B; Erdmann, E; Spanheimer, R, 2010)
"Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure."5.12Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). ( Charbonnel, B; Dormandy, JA; Erdmann, E; Massi-Benedetti, M; Skene, AM; Spanheimer, R; Standl, E; Tan, M; Wilcox, RG; Yates, J, 2007)
"The pioglitazone treatment significantly reduced hyperglycemia, hyperinsulinemia, and HbA(1c) levels and increased plasma adiponectin concentrations relative to the control group (P < 0."5.10Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. ( Kono, S; Kuzuya, H; Nakao, K; Ogawa, Y; Satoh, N; Shimatsu, A; Sugawara, A; Sugiyama, H; Tagami, T; Uesugi, H; Usui, T; Yamada, K, 2003)
"The goal of the meta-analysis was to evaluate the effect of pioglitazone on the primary and secondary prevention of cardiovascular diseases (CVDs) and renal adverse events in patients with or at high risk of type 2 diabetes mellitus (T2DM)."5.05Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. ( Huang, Y; Ji, X; Shen, L; Wang, X; Wang, Y; Zhou, Y, 2020)
"Pioglitazone has diverse multiple effects on metabolic and inflammatory processes that have the potential to influence cardiovascular disease pathophysiology at various points in the disease process, including atherogenesis, plaque inflammation, plaque rupture, haemostatic disturbances and microangiopathy."4.86Pioglitazone and mechanisms of CV protection. ( Erdmann, E; Wilcox, R, 2010)
" Available data suggest that pioglitazone can delay progression of atherosclerosis in patients with type 2 diabetes, as shown by the PERISCOPE and CHICAGO studies, and that it can reduce the rate of clinical CV events as shown by PROactive."4.85Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. ( Fisher, M, 2009)
"The antidiabetic compound pioglitazone, an activator of the intracellular peroxisome proliferator-activated receptor-gamma, and decreases metabolic and vascular insulin resistance."4.83Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. ( Forst, T; Pfützner, A; Schneider, CA, 2006)
" This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model."3.85Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017)
"Patients with type 2 diabetes face an increased risk of macrovascular disease compared to those without."3.82PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. ( Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R, 2007)
"To observe effects of the drug pioglitazone on expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in diabetic rats with hindlimb ischemia, and explore the role of pioglitazone in angiogenesis after ischemia and its possible mechanism."3.80Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats. ( Bai, SJ; Gao, X; Ye, XM; Zhang, J; Zhang, M, 2014)
"The present study demonstrated that pioglitazone can restore the nocturnal BP declines in parallel to reductions in the HOMA index, suggesting that insulin resistance may play an important role in the genesis of circadian BP rhythms."3.74Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. ( Anan, F; Eshima, N; Fukunaga, N; Iwao, T; Kaneda, K; Masaki, T; Okada, K; Saikawa, T; Teshima, Y; Umeno, Y; Wakasugi, K; Yonemochi, H; Yoshimatsu, H, 2007)
"Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow-up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design."2.82Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. ( Erdmann, E; Harding, S; Lam, H; Perez, A, 2016)
"The double-blind period bladder cancer imbalance did not persist in follow-up."2.79Observational follow-up of the PROactive study: a 6-year update. ( Erdmann, E; Perez, A; Song, E; Spanheimer, R; van Troostenburg de Bruyn, AR, 2014)
"Pioglitazone use in combination with insulin resulted in a sustained improved glycemic control and allowed the treatment regimens to be simplified and the insulin doses reduced."2.75Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). ( Birkeland, K; Charbonnel, B; Davidson, J; DeFronzo, R; Pirags, V; Scheen, A; Schmitz, O, 2010)
"The study included 15 subjects with type 2 diabetes with normoalbuminuria (age, 60."2.73Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. ( Kashiwagi, A; Maeda, K; Maegawa, H; Nakao, K; Nishio, Y; Ugi, S; Uzu, T, 2007)
"Thirty subjects with type 2 diabetes were initiated on intensive insulin therapy (continuous subcutaneous insulin infusion [n = 12] or multiple daily injections [n = 18]) and then randomized to either pioglitazone (PIO group;45 mg/day), ramipril (RAM group; 10 mg/day), or placebo (PLC group) for 36 weeks."2.73Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. ( Cersosimo, E; Cusi, K; DeFronzo, R; Fernandez, M; Musi, N; Sriwijilkamol, AA; Triplitt, C; Wajcberg, E, 2008)
"The treatment with pioglitazone in type 2 diabetic patients significantly reduced leptin."2.72A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. ( Fukui, T; Itoh, S; Katagiri, T; Kawamura, K; Konno, N; Kusuyama, T; Nishio, K; Sakurai, M; Shigemitsu, M, 2006)
"Pioglitazone treatment can convey direct protection against cytokine (TNF-alpha)-induced endothelial dysfunction in humans with an increased cardiovascular risk due to type 2 diabetes."2.72TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. ( de Koning, EJ; Martens, FM; op 't Roodt, J; Rabelink, TJ; Visseren, FL, 2006)
"Type 2 diabetes has long been recognized as an independent risk factor for cardiovascular disease (CVD), including coronary artery disease (CAD), stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure."2.47Macrovascular effects and safety issues of therapies for type 2 diabetes. ( Plutzky, J, 2011)
"Treatment with pioglitazone produced improvement in several parameters, such as systolic blood pressure and lipid levels, including a 14% increase in HDL cholesterol, and reduced CIMT progression, compared with glimepiride."2.45The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. ( Davidson, M; Mazzone, T; Polonsky, T, 2009)
"The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States."2.44PPARgamma agonists and coronary atherosclerosis. ( Chilton, R; Sulistio, MS; Thukral, N; Zion, A, 2008)
"Type 2 diabetes mellitus has become a true epidemic and significant growth is expected in the next decades."2.43[Pioglitazone. Review of its metabolic and systemic effects]. ( Cebrián Blanco, S; Durán García, S; Rodríguez Bernardino, A, 2005)
"Insulin resistance is associated with inflammation and has a key role in atherogenesis."2.43Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. ( Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R, 2006)
"Insulin resistance is now considered to be major pathogenesis for diabetic macroangiopathy."2.43[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin]. ( Daita, H; Mokuno, H; Tamura, H, 2006)
"The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments."2.42Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004)
"Pioglitazone is a thiazolidinedione that increases insulin sensitivity in target tissues."2.41Pharmacokinetics and clinical efficacy of pioglitazone. ( Hanefeld, M, 2001)
"Patients with type 2 diabetes (T2DM) are at risk of long-term vascular complications."1.38Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. ( Alperin, P; Blickensderfer, A; Cohen, M; Gaebler, JA; Han, J; Hoogwerf, B; Maggs, D; Pencek, R; Peskin, B; Soto-Campos, G; Wintle, M, 2012)
"Incident myocardial infarction, congestive heart failure, and all cause mortality."1.35Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. ( Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR, 2009)
"This study of patients with Type 2 diabetes failed to find evidence that short-term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first-line diabetes therapy."1.33Pioglitazone initiation and subsequent hospitalization for congestive heart failure. ( Ahmed, AT; Karter, AJ; Liu, J; Moffet, HH; Parker, MM, 2005)
"Treatment with pioglitazone significantly improved glucose and lipid metabolism."1.30Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. ( Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T, 1997)

Research

Studies (80)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (1.25)18.2507
2000's50 (62.50)29.6817
2010's27 (33.75)24.3611
2020's2 (2.50)2.80

Authors

AuthorsStudies
Zhou, Y1
Huang, Y1
Ji, X1
Wang, X1
Shen, L1
Wang, Y1
Yen, CL1
Wu, CY1
See, LC1
Li, YJ1
Tseng, MH1
Peng, WS1
Liu, JR1
Chen, YC2
Yen, TH1
Tian, YC1
Yang, CW1
Anderson, GF1
Yang, HY1
Gao, H1
Li, H1
Li, W1
Shen, X1
Di, B1
Patorno, E1
Gopalakrishnan, C1
Brodovicz, KG1
Meyers, A1
Bartels, DB1
Liu, J2
Kulldorff, M1
Schneeweiss, S1
Erdmann, E10
Song, E1
Spanheimer, R3
van Troostenburg de Bruyn, AR1
Perez, A2
Nitta, Y2
Tahara, N2
Tahara, A2
Honda, A1
Kodama, N2
Mizoguchi, M2
Kaida, H2
Ishibashi, M2
Hayabuchi, N2
Ikeda, H2
Yamagishi, S2
Imaizumi, T2
Zhang, M1
Gao, X1
Bai, SJ1
Ye, XM1
Zhang, J1
Heng, XP1
Li, L1
Huang, SP1
Chen, Y1
Lin, MX1
Zhuang, HS1
Yan, QF1
Yang, LQ1
Chen, L1
Lin, Q1
Cheng, XL1
Chen, ML1
Lan, YL1
Wang, ZT1
Yao, SH1
Zhang, ZS1
Hong, SJ1
Choi, SC1
Cho, JY1
Joo, HJ1
Park, JH1
Yu, CW1
Lim, DS1
Shinke, T1
Ryder, RE2
Harding, S1
Lam, H1
DeFronzo, RA2
Chilton, R2
Norton, L1
Clarke, G1
Abdul-Ghani, M1
Singh, S1
Furberg, CD1
Krentz, A1
Barnett, AH1
Polonsky, T1
Mazzone, T1
Davidson, M1
Fisher, M1
Lambley, RG1
Vahdani, K2
Konstantinidis, A1
Booth, A1
Kaku, K1
Daida, H1
Kashiwagi, A2
Yamashina, A1
Yamazaki, T1
Momomura, S1
Iwase, T1
Yamasaki, Y1
Nagatsuka, K1
Kitagawa, K1
Kawamori, R1
Fukuda, M1
Nakamura, T1
Kataoka, K1
Nako, H1
Tokutomi, Y1
Dong, YF1
Ogawa, H1
Kim-Mitsuyama, S1
Wilcox, R2
Tzoulaki, I1
Molokhia, M1
Curcin, V1
Little, MP1
Millett, CJ1
Ng, A1
Hughes, RI1
Khunti, K1
Wilkins, MR1
Majeed, A1
Elliott, P1
Hanefeld, M2
Schönauer, M1
Forst, T2
Charbonnel, B5
DeFronzo, R3
Davidson, J1
Schmitz, O1
Birkeland, K1
Pirags, V1
Scheen, A1
Asakura, M1
Kim, J1
Asanuma, H1
Kitakaze, M1
Alosh, M1
Huque, MF1
Quinn, CE1
Lockhart, CJ1
Hamilton, PK1
Loughrey, CM1
McVeigh, GE1
Esposito, K1
Maiorino, MI1
Di Palo, C1
Gicchino, M1
Petrizzo, M1
Bellastella, G1
Saccomanno, F1
Giugliano, D1
Joya-Galeana, J1
Fernandez, M2
Cervera, A1
Reyna, S1
Ghosh, S1
Triplitt, C2
Musi, N2
Cersosimo, E2
Pfister, R1
Cairns, R1
Schneider, CA3
Plutzky, J1
Tawakol, A1
Finn, AV1
Oba, T1
Mawatari, K1
Yasukawa, H1
Harada, H1
Marwick, TH1
Narula, J1
Gaebler, JA1
Soto-Campos, G1
Alperin, P1
Cohen, M1
Blickensderfer, A1
Wintle, M1
Maggs, D1
Hoogwerf, B1
Han, J1
Pencek, R1
Peskin, B1
Satoh, N1
Ogawa, Y1
Usui, T1
Tagami, T1
Kono, S1
Uesugi, H1
Sugiyama, H1
Sugawara, A1
Yamada, K1
Shimatsu, A1
Kuzuya, H1
Nakao, K2
Dormandy, J2
Massi-Benedetti, M4
Skene, A1
Belcher, G1
Lambert, C1
Goh, KL1
Edwards, G1
Valbuena, M1
Shah, M1
Kolandaivelu, A1
Fearon, WF1
Cho, L1
Lewis, BE1
Steen, LH1
Leya, FS1
Karter, AJ1
Ahmed, AT1
Moffet, HH1
Parker, MM1
Smyth, SS1
Jennings, JL1
Freemantle, N1
Aumiller, J1
Nishio, K1
Sakurai, M1
Kusuyama, T1
Shigemitsu, M1
Fukui, T1
Kawamura, K1
Itoh, S1
Konno, N1
Katagiri, T1
Pratley, RE1
Rodríguez Bernardino, A1
Cebrián Blanco, S1
Durán García, S1
Schmitz, OE1
Brock, B1
Rungby, J1
Madsbad, S1
Martens, FM1
Rabelink, TJ1
op 't Roodt, J1
de Koning, EJ1
Visseren, FL1
Ríos-Vázquez, R1
Marzoa-Rivas, R1
Gil-Ortega, I1
Kaski, JC1
Pfützner, A1
Tamura, H1
Mokuno, H1
Daita, H1
Nitschmann, S1
Ruiz, E1
Redondo, S1
Gordillo-Moscoso, A1
Tejerina, T1
Takebayashi, K1
Suetsugu, M1
Wakabayashi, S1
Aso, Y1
Inukai, T1
Valentine, WJ1
Bottomley, JM1
Palmer, AJ1
Brändle, M1
Foos, V1
Williams, R1
Dormandy, JA2
Yates, J3
Tan, MH1
Maegawa, H1
Nishio, Y1
Ugi, S1
Maeda, K1
Uzu, T1
Wilcox, RG1
Skene, AM1
Tan, M1
Standl, E1
Anan, F1
Masaki, T1
Fukunaga, N1
Teshima, Y1
Iwao, T1
Kaneda, K1
Umeno, Y1
Okada, K1
Wakasugi, K1
Yonemochi, H1
Eshima, N1
Saikawa, T1
Yoshimatsu, H1
Wajcberg, E1
Sriwijilkamol, AA1
Cusi, K1
Ferrannini, E1
Schernthaner, G1
Stojanovska, L1
Honisett, SY1
Komesaroff, PA1
Bourassa, MG1
Berry, C1
Sulistio, MS1
Zion, A1
Thukral, N1
Yoshimoto, T1
Naruse, M1
Nishikawa, M1
Naruse, K1
Tanabe, A1
Seki, T1
Imaki, T1
Demura, R1
Aikawa, E1
Demura, H1
Brunetti, P1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631]70 participants (Actual)Interventional2007-05-31Completed
International Multicenter Trial on the Prognostic Value of Arterial 18F-FDG PET Imaging in Patients With History of Myocardial Infarction[NCT05138718]2,041 participants (Anticipated)Observational [Patient Registry]2021-12-01Recruiting
An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications.[NCT02678676]3,599 participants (Actual)Observational [Patient Registry]2004-11-30Completed
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692]Phase 3500 participants (Anticipated)Interventional2021-08-31Suspended (stopped due to Administrative decision of the investigation direction)
Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671]Phase 3203 participants (Actual)Interventional2014-06-30Completed
PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993]Phase 34,373 participants (Actual)Interventional2001-05-31Completed
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.[NCT01144338]Phase 314,752 participants (Actual)Interventional2010-06-18Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Incidences With Malignancies

Percentage of participants with incidences of at least 1 malignancy was reported. All malignancies included adrenal, biliary, bladder, brain, breast, cervix, colon/rectal, gastric, hematological, hepatic, lung, mesothelioma, metastases, oesophageal, oropharyngeal, ovarian/uterine, pancreas, prostate, renal, skin and others. (NCT02678676)
Timeframe: Up to Year 10

Interventionpercentage of participants (Number)
Pioglitazone12.9
Placebo13.2

Percentage of Participants With First Occurrence of Macro-vascular Event or Death

The composite macro-vascular event or death included all-cause mortality, non-fatal myocardial infarction, cardiac intervention, stroke, major leg amputation (above the ankle), bypass surgery or revascularization in the leg. The percentage of participants in the observational study population having first occurrence of macro-vascular event or death during the 10-year observational study period was analyzed. The data were analyzed using the Cox regression with respect to time to the first occurrence of macro-vascular event or death. (NCT02678676)
Timeframe: Up to Year 10

Interventionpercentage of participants (Number)
Pioglitazone58
Placebo60.3

Reviews

20 reviews available for pioglitazone and Diabetic Angiopathies

ArticleYear
Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.
    The Journal of clinical endocrinology and metabolism, 2020, 05-01, Volume: 105, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Chemoprevention; Diabetes Mellitus, Type 2;

2020
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:5

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat

2016
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Diabetes/metabolism research and reviews, 2009, Volume: 25, Issue:2

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents;

2009
Redefining the role of thiazolidinediones in the management of type 2 diabetes.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic An

2009
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
    Trends in cardiovascular medicine, 2009, Volume: 19, Issue:3

    Topics: Carotid Arteries; Chicago; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human

2009
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
    International journal of clinical practice, 2009, Volume: 63, Issue:9

    Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diab

2009
Pioglitazone and mechanisms of CV protection.
    QJM : monthly journal of the Association of Physicians, 2010, Volume: 103, Issue:4

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angi

2010
[Glycemic control and cardiovascular benefit: What do we know today?].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:7

    Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat

2010
Macrovascular effects and safety issues of therapies for type 2 diabetes.
    The American journal of cardiology, 2011, Aug-02, Volume: 108, Issue:3 Suppl

    Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Pro

2011
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
    International journal of clinical practice, 2004, Volume: 58, Issue:9

    Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glicl

2004
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
    BMJ (Clinical research ed.), 2005, Oct-08, Volume: 331, Issue:7520

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Randomi

2005
[Pioglitazone. Review of its metabolic and systemic effects].
    Revista clinica espanola, 2005, Volume: 205, Issue:12

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agen

2005
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:4

    Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Hu

2006
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
    Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4

    Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Diabetic Angiopathie

2006
[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:11

    Topics: Adiponectin; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabeti

2006
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
    Vascular health and risk management, 2007, Volume: 3, Issue:4

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic An

2007
The anti-atherogenic effects of thiazolidinediones.
    Current diabetes reviews, 2007, Volume: 3, Issue:1

    Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diab

2007
PPARgamma agonists and coronary atherosclerosis.
    Current atherosclerosis reports, 2008, Volume: 10, Issue:2

    Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopath

2008
Pharmacokinetics and clinical efficacy of pioglitazone.
    International journal of clinical practice. Supplement, 2001, Issue:121

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Risk Fa

2001
Pioglitazone: the future.
    International journal of clinical practice. Supplement, 2001, Issue:121

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Forecasting; Humans; Hyp

2001

Trials

23 trials available for pioglitazone and Diabetic Angiopathies

ArticleYear
Observational follow-up of the PROactive study: a 6-year update.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi

2014
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:11

    Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease;

2013
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:11

    Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease;

2013
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:11

    Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease;

2013
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:11

    Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease;

2013
Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:4

    Topics: Aged; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperplasi

2015
Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi

2016
Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Current medical research and opinion, 2009, Volume: 25, Issue:12

    Topics: Adult; Aged; Asian People; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Bli

2009
Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:5

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Dia

2010
Effect of pioglitazone on endothelial function in impaired glucose tolerance.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Fe

2010
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
    Journal of diabetes, 2010, Volume: 2, Issue:3

    Topics: Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic An

2010
Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:5

    Topics: Adult; Aged; Body Mass Index; Cell Survival; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dia

2011
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Diabetes/metabolism research and reviews, 2011, Volume: 27, Issue:4

    Topics: Adult; Body Mass Index; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabet

2011
A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study.
    International journal of cardiology, 2013, Jan-10, Volume: 162, Issue:2

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi

2013
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive

2011
Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.
    Diabetes care, 2003, Volume: 26, Issue:9

    Topics: Adiponectin; Arteriosclerosis; Blood Pressure; Body Mass Index; C-Reactive Protein; Diabetes Mellitu

2003
The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
    Diabetes care, 2004, Volume: 27, Issue:7

    Topics: Adult; Cardiovascular Diseases; Demography; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female

2004
A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.
    Diabetes care, 2006, Volume: 29, Issue:1

    Topics: Aged; Blood Pressure; Coronary Disease; Coronary Restenosis; Cytokines; Diabetes Mellitus, Type 2; D

2006
[The place of Glitazones in the treatment of diabetes: after the PROactive study].
    Ugeskrift for laeger, 2006, May-01, Volume: 168, Issue:18

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; H

2006
TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
    European heart journal, 2006, Volume: 27, Issue:13

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Humans

2006
Retinol binding protein-4 levels and clinical features of type 2 diabetes patients.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:7

    Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Age

2007
Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes.
    Endocrine journal, 2007, Volume: 54, Issue:4

    Topics: Adiponectin; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies;

2007
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
    Diabetes care, 2007, Volume: 30, Issue:11

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Hear

2007
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
    Diabetes care, 2008, Volume: 31, Issue:1

    Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ang

2008
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
    Vascular health and risk management, 2007, Volume: 3, Issue:4

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic An

2007
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
    Journal of the American Society of Nephrology : JASN, 2008, Volume: 19, Issue:1

    Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Femal

2008

Other Studies

38 other studies available for pioglitazone and Diabetic Angiopathies

ArticleYear
Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study.
    Diabetes care, 2020, Volume: 43, Issue:10

    Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Diabetes Mellit

2020
Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Dec-26, Volume: 23

    Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Diabetes Complications; Diabetes Melli

2017
Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:8

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans

2019
Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:9

    Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diab

2014
[Effect of dangua recipe on glycolipid metabolism and VCAM-1 and its mRNA expression level in Apo E(-/-) mice with diabetes mellitus].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2014, Volume: 34, Issue:9

    Topics: Animals; Apolipoproteins E; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Angiopathies; D

2014
Pioglitazone revisited to illuminate contemporary vascular reparative therapy in the era of drug-eluting stents.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:4

    Topics: Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Age

2015
Pioglitazone: reports of its death are greatly exaggerated - it is alive and ready to resume saving lives.
    Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:4

    Topics: Animals; Carcinogens; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Observational Studies as T

2015
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:1

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Piogli

2009
Rosiglitazone and pioglitazone. Beware macular oedema.
    BMJ (Clinical research ed.), 2009, Sep-22, Volume: 339

    Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular E

2009
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
    Journal of hypertension, 2010, Volume: 28, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds;

2010
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
    BMJ (Clinical research ed.), 2009, Dec-03, Volume: 339

    Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon

2009
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
    BMJ (Clinical research ed.), 2009, Dec-03, Volume: 339

    Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon

2009
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
    BMJ (Clinical research ed.), 2009, Dec-03, Volume: 339

    Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon

2009
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
    BMJ (Clinical research ed.), 2009, Dec-03, Volume: 339

    Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon

2009
[Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:5

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Metabolic Syndrome; P

2010
A consistency-adjusted alpha-adaptive strategy for sequential testing.
    Statistics in medicine, 2010, Jul-10, Volume: 29, Issue:15

    Topics: Algorithms; Biostatistics; Captopril; Clinical Trials as Topic; Data Interpretation, Statistical; Di

2010
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art

2011
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus,

2011
Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Vascular health and risk management, 2012, Volume: 8

    Topics: Aged; Biomarkers; Blood Glucose; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type

2012
[Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
    MMW Fortschritte der Medizin, 2002, May-23, Volume: 144, Issue:21

    Topics: Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans

2002
[Early effect of therapy with pioglitazone. Vascular damage significantly reduced].
    MMW Fortschritte der Medizin, 2002, May-23, Volume: 144, Issue:21

    Topics: Arteriosclerosis; Carotid Stenosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic An

2002
[Vascular damage decides prognosis of type 2 diabetic patients. Lowering blood glucose is not enough].
    MMW Fortschritte der Medizin, 2002, May-02, Volume: 144, Issue:18

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Prognos

2002
[Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
    MMW Fortschritte der Medizin, 2003, Jun-05, Volume: 145, Issue:23

    Topics: Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Thera

2003
[Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
    MMW Fortschritte der Medizin, 2003, Sep-11, Volume: 145, Issue:37

    Topics: Arteriosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; H

2003
[Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
    MMW Fortschritte der Medizin, 2003, Oct-09, Volume: 145, Issue:41

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Approval; Drug Therapy, Combination; Germany;

2003
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
    Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:7

    Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans;

2004
Pioglitazone-induced heart failure despite normal left ventricular function.
    The American journal of medicine, 2004, Dec-15, Volume: 117, Issue:12

    Topics: Aged; Diabetes Mellitus; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents;

2004
Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.
    Cardiology, 2005, Volume: 104, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Cause of Death; Coronary Circulation; Coronary Stenosis; Diabe

2005
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Hospi

2005
PPARgamma agonists: a new strategy for antithrombotic therapy.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:10

    Topics: Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hyperglycemia; Hypoglycemic Agents; Pioglitazone

2005
[New studies, new strategies, new guidelines: so that diabetic patients will live longer].
    MMW Fortschritte der Medizin, 2005, Oct-13, Volume: 147, Issue:41

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Germany; Glycated Hemoglo

2005
[How does the PROactive Study change therapy of diabetes?].
    MMW Fortschritte der Medizin, 2005, Oct-13, Volume: 147, Issue:41

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agen

2005
The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.
    Current diabetes reports, 2006, Volume: 6, Issue:1

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Thiazol

2006
[Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].
    Der Internist, 2007, Volume: 48, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi

2007
[New subgroup analysis of the PROactive Study. Risk for recurrent stroke cut in half].
    MMW Fortschritte der Medizin, 2006, Oct-12, Volume: 148, Issue:41

    Topics: Cerebral Infarction; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hum

2006
Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:2

    Topics: Activin Receptors; Activin Receptors, Type I; Aged; Anaplastic Lymphoma Kinase; Apoptosis; Atheroscl

2007
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:9

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female

2007
Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
    European journal of clinical investigation, 2007, Volume: 37, Issue:9

    Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circa

2007
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
    Current atherosclerosis reports, 2008, Volume: 10, Issue:2

    Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Melli

2008
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
    The American journal of physiology, 1997, Volume: 272, Issue:6 Pt 1

    Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Dia

1997
[Life expectancy decreased by 1/3rd. Who to sink the vascular risk of type 2 diabetic patients?].
    MMW Fortschritte der Medizin, 2001, Dec-06, Volume: 143, Issue:49-50

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Surviva

2001